ITEM VIEW

Malignant pericardial effusion in breast cancer: Terminal event or treatable complication?

dc.contributor.authorSwanepoel E.
dc.contributor.authorApffelstaedt J.P.
dc.date.accessioned2011-05-15T16:05:04Z
dc.date.available2011-05-15T16:05:04Z
dc.date.issued1997
dc.identifier.citationJournal of Surgical Oncology
dc.identifier.citation64
dc.identifier.citation4
dc.identifier.issn224790
dc.identifier.other10.1002/(SICI)1096-9098(199704)64:4<308::AID-JSO11>3.0.CO;2-Z
dc.identifier.urihttp://hdl.handle.net/10019.1/12958
dc.description.abstractBackground: Few data are available on malignant pericardial effusion (MPCE) in breast cancer. We identify the patient prone to develop MPCE, describe the result of surgical management, and try to identity a subgroup of patients who do not benefit from surgical management. Method: We performed an audit of our policy of active search for MPCE in breast cancer patients and its treatment by subxiphoid pericardial fenestration. Result: Nineteen patients with MPCE had a mean of 3.2 other sites of recurrence: 17 had pleural recurrence. Six patterns had exertional dyspnea and 13 had dyspnea at rest: three needed emergency pericardiocentesis. An average of 740 ml of fluid was recovered; cytology was diagnostic in 11 cases and histopathology in 10 cases. At discharge, six patients had no dyspnea and six had exertional dyspnea. Of 10 patients who did not receive systemic treatment, eight died within 30 days. Nine patients who received systemic treatment had an average survival of 8.3 months. Conclusions: Patients with pleural recurrence presenting with dyspnea should be evaluated for the presence of a MPCE. Subxiphoid pericardial fenestration is the treatment of choice. Patients who will not receive systemic treatment should be managed conservatively.
dc.subjectcyclophosphamide
dc.subjectdoxorubicin
dc.subjectfluorouracil
dc.subjectmethotrexate
dc.subjectmitomycin c
dc.subjectmitoxantrone
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectbreast cancer
dc.subjectclinical article
dc.subjectdyspnea
dc.subjectfemale
dc.subjectfenestration
dc.subjecthealth care policy
dc.subjecthuman
dc.subjecthuman cell
dc.subjecthuman tissue
dc.subjectpatient selection
dc.subjectpericardial effusion
dc.subjectpriority journal
dc.subjectrecurrence risk
dc.subjectrisk benefit analysis
dc.subjectAdult
dc.subjectAged
dc.subjectBone Neoplasms
dc.subjectBreast Neoplasms
dc.subjectFemale
dc.subjectHumans
dc.subjectLung Neoplasms
dc.subjectLymphatic Metastasis
dc.subjectMiddle Aged
dc.subjectNeoplasm Recurrence, Local
dc.subjectPericardial Effusion
dc.subjectPericardial Window Techniques
dc.titleMalignant pericardial effusion in breast cancer: Terminal event or treatable complication?
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW